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Summary 
The ability of a human cytomegalovirus-encoded ho- 
molog of MHC class I molecules to serve as a peptide 
receptor was investigated. Sequencing of peptide ma- 
terial eluted from the purified viral protein revealed a 
mixture of endogenous peptides with characteristics 
similar to those eluted from conventional class I mole- 
cules, that is, anchor residues, and a predominance 
of short peptides derived from cytoplasmic proteins. 
The possible function(s) of this viral MHC homolog are 
discussed in light of the finding that it binds endoge- 
nous peptides. 
Introduction 
Class I major histocompatibilitycomplex (MHC) molecules 
are polymorphic cell surface glycoproteins that participate 
in the immune surveillance against viruses by displaying 
peptides from endogenously synthesized proteins to T 
cells (Townsend and Bodmer, 1989). Class I molecules 
preferentially bind short (8- or 9-mer) peptides in the endo- 
plasmic reticulum during the assembly of the heavy chain 
with the class I light chain (p2-microglobulin; &m), and 
stable cell surface expression requires bound peptide 
(Townsend and Bodmer, 1989; Ljunggren et al., 1990; 
Townsend et al., 1990). T cell receptors on cytotoxic T 
lymphocytes recognize a combination of a particular pep- 
tide and a class I allele. In an uninfected cell, MHC mole- 
cules are occupied with peptides derived from self- 
proteins to which the immute system is tolerant. In an 
infected cell, some class I molecules present virally de- 
rived peptides to which the immune system reacts. Viruses 
have evolved a number of strategies to evade the immune 
response, including down-regulation of cell surface class 
I MHC molecules to escape T cell recognition (Maudsley 
and Pound, 1991). For example, cells infected by human 
cytomegalovirus (HCMV) show a dramatic reduction of cell 
surface class I molecules (Browne et al., 1990). However, 
although HCMV-infected cells are immune to destruction 
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by T cells, natural killer (NK) cells specifically lyse cells 
that lack class I molecules (Ljunggren and Karre, 1990). 
Lysis is inhibited when an inhibitory receptor on the NK 
cell is engaged by a peptide-filled class I molecule on the 
target cell (Correa and Raulet, 1995; Malnati et al., 1995). 
HCMV encodes a P2m-binding class I MHC heavy chain 
homolog within its genome (Beck and Barrell, 1988; 
Browne et al., 1990). Sequence comparisons (Beck and 
Barrell, 1988) suggest that the structure of the viral homo- 
log includes the a helices and p sheet within the al and 
a2 domains that form the MHC peptide binding site (Figure 
l), although the sequence identity between the HCMV 
class I homolog and conventional class I molecules is low 
(-24% in the al and a2 domains). Another MHC homo- 
log, the neonatal Fc receptor, shares a similarly low level 
of sequence identity with class I molecules (Simister and 
Mostov, 1989a, 1989b). In this case, crystallographic anal- 
ysis revealed that the folding topology within the al and 
a2 domains of the two types of proteins is the same (Bur- 
meister et al., 1994), but the Fc receptor MHC homolog 
does not bind peptides(Raghavan et al., 1993; Burmeister 
et al., 1994). The high thermal stability of the neonatal Fc 
receptor in the absence of bound peptide (Raghavan et 
al., 1993) compared with the relative instability of empty 
class I MHC molecules (Townsend and Bodmer, 1989; 
Ljunggren et al., 1990; Townsend et al., 1990; Fahnestock 
et al., 1992) is apparently caused by closure of the counter- 
part of the receptor MHC peptide binding site by move- 
ment of the helix within the a2 domain and insertion of an 
arginine side chain into pocket A (Burmeister et al., 1994). 
This result demonstrates that the assumption that peptide 
binding is required for stability of the MHC fold must be 
tested for newly discovered MHC homologs. 
To gain structural and functional insight into the HCMV 
class I homolog, we tested purifed protein for the presence 
of endogenous peptides. We find that the viral homolog 
indeed binds peptides, and that the sequences of eluted 
peptides reveal a clear motif with characteristics similar 
to the motifs elucidated for peptides binding to different 
class I alleles (Rammensee et al., 1993). These results are 
analyzed using the three-dimensional structure of class I 
molecules as a model for the peptide binding site of the 
viral homolog, and hypotheses regarding the functional 
significance of the discovery of peptide binding are pre- 
sented. 
Results and Discussion 
Expression of a Secreted Form of the HCMV 
Class I Homolog 
To investigate whether the HCMV class I homolog serves 
as a peptide receptor, and whether bound peptides resem- 
ble those associated with class I molecules, we analyzed 
asolubleform of the HCMV heavy chain/human Prim heter- 
odimer for endogenous peptides. A secreted form of the 
HCMV class I heavy chain homolog (the product of the 
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Figure 1. Carbon a Backbone of the al and a2 Domains of a Class I MHC Molecule as a Model for the Structure of the Corresponding Portion 
of the ULl8 HCMV Class I MHC Homolog 
The approximate locations of pockets A, 6, and F in the class I structure (HLA-AS; Bjorkman et al., 1987; Saper et al., 1991) are indicated. Regions 
in which insertions or deletions in UL18 compared with A2 (based upon the sequence alignment in Beck and Barrell, 1988) are shown as broken 
line rectangles, indicating that the structures of these regions of UL18 cannot be modeled upon the A2 structure. Pocket A tyrosines 7, 59, 159, 
and 171 (class I numbering) are highlighted. The corresponding residues in UL18 are tyrosines 5, 59, 169, and 181 (see Experimental Procedures 
for a description of the UL18 numbering scheme). This figure was generated using the program SETOR (Evans, 1993). 
HCMV UL18 gene; Beck and Barrell, 1988) was expressed 
together with human Pnrn in Chinese hamster ovary (CHO) 
cells. UL18&m heterodimers were purified from the su- 
pernatants of transfected cells using an anti-&m immu- 
noaffinitycolumn,followed bysizeexclusionchromatogra- 
phy. SDS-PAGE analysis of the purified protein shows 
two bands running with apparent molecular masses of 66 
kDa (corresponding to the truncated heavy chain; residues 
1 to 301) and 12 kDa (corresponding to human Snrn) (Figure 
2). The UL18 heavy chain is heavily glycosylated (13 po- 
tential N-linked glycosylation sites; Beck and Barrell, 1988) 
and therefore runs with a higher apparent molecular mass 
than a secreted class I MHC molecule (H-2Kd) expressed 
in CHO cells using similar methods (Fahnestock et al., 
1992) (Figure 2). None of the potential N-linked glycosyla- 
tion sites on the UL18 al and a2 domains appear to be in 
locations that would inierfere with peptide binding, based 
upon an alignment (Beck and Barrell, 1988) of the UL18 
and class I sequences. 
Analysis of Peptides Eluted from the HCMV 
Class I Homolog 
Purified UL18&m heterodimers were treated with acetic 
acid to dissociate potential peptide material (Rdtzschke 
et al., 1990; Van Bleek and Nathenson, 1990; Jardetzky 
et al., 1991), and low molecular weight acid eluates were 
sequenced by Edman degradation. As a positive control, 
secreted H-2Kd (Fahnestock et al., 1992) was subjected 
to the same treatment. Both eluates show the presence 
of peptides (Table 1). The characteristics of the Kd eluate 
are similar to those previously reported (Raghavan et al., 
1993; Fahnestock et al., 1994) and consistent with the 
known requirement for a tyrosine anchor at position 2 and 
the preferred length of 9 aa for Kd-binding peptides (Ram- 
mensee et al., 1993). These results demonstrate that the 
sequences of peptides eluted from a secreted version of 
a class I molecule conform to the allele-specific motif pre- 
viously identified for the membrane-bound version (Ram- 
mensee et al., 1993) and suggests that peptides eluted 
from the soluble UL18 heterodimers should reflect those 
that are bound by the membrane version of the protein. 
We can rule out the suggestion that the peptides in the 
UL18 acid eluate represent a contaminant or are derived 
from a protein other than UL18 by two arguments: first, 
calculations based upon a comparison with the yield of 
peptides eluted from secreted Kd suggest an essentially 
1 :l molar ratio of eluted peptide to UL18 protein (see Ex- 
perimental Procedures). Second, using the same elution 
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Kd Table 1. pmol of Amino Acids Recovered from Acid Elutions 
Cycle number UL16 H-2Ka 
21.5+ 
14.5-+ 
6.5+ 
Figure 2. SDS/l3% PAGE Comparison of Purified Secreted UL18 
and a Secreted Class I MHC Molecule (H-2Kd) 
Lane 1, Molecular mass markers. Lane 2, secreted UL18. Lane 3, 
secreted H-2Kd. 
protocol and pool sequencing procedure, we previously 
demonstrated that acid eluates of ribonuclease and of puri- 
fied secreted neonatal Fc receptor expressed in CHO cells 
(Gastinel et al., 1992) did not reveal the presence of pep- 
tides (Raghavan et al., 1993). Thus, the elution and se- 
quencing procedure itself is not inherently subject to con- 
tamination. The near stoichiometric amount of peptide in 
the UL18 eluate negates the possibility that the peptides 
were eluted from another protein copurifying with UL18, 
since no other major bands are apparent upon SDS- 
PAGE analysis of purified UL18 protein (Figure 2). 
The pool sequence obtained from the UL18 eluate 
shows a strong predominance of leucine and methionine 
at position 2 (Table l), reminiscent of the use of position 
2 as an anchor residue for the peptide ligands of a number 
of class I alleles, including Kd (Rammensee et al., 1993). 
The Kd eluate shows the expected drop in the total pico- 
moles of amino acids recovered after cycle 9 (Rammensee 
et al., 1993). There is a corresponding drop in recovered 
amino acids in the UL18 eluate after cycle 8, but se- 
quences of individual peptides show that some longer pep- 
tides bind to the viral class I homolog (Table 2). 
To characterize further the peptides eluted from UL18, 
the acid-eluted pools were fractionated by reverse-phase 
1 376 175 
2 196 (Leu, Met = 175) 111 (Tyr = 77) 
3 131 (Pro = 64) 88 
4 42 31 
5 75 46 
6 54 23 
7 60 32 
8 34 19 
9 5 11 
IO 4 0 
The total yield of amino acids from each sequencing cycle is presented 
for peptides eluted from equivalent amounts of UL18 and H-2Kd hetero- 
dimers. Only those amino acid residues that showed an increase in 
the absolute amount recovered compared the previous cycle were 
considered significant. The acid eluate used for pool sequencing was 
derived independently from a different preparation of UL18 than the 
eluate used for the sequencing results presented in Table 2. The same 
sequence motif for ULIB-binding peptides is discernible in both. 
high pressure liquid chromatography (HPLC) (Figure 3), 
and single peaks from these separations were collected 
and sequenced. Comparison of the sequence data in Ta- 
ble 2 and Figure 4 with the pool sequencing data in Table 1 
reveals a motif for peptides that bind to UL18, the dominant 
features being a preference for leucine or methionine at 
position 2, proline at position 3, and a hydrophobic amino 
acid at position 9. This motif was found in two independent 
UL18 acid eluates derived from two different preparations 
of purified UL18. We can be confident that the majority 
of peptides binding to UL18 exhibit these characteristics 
because the predominant features of the motif are evident 
in the results from the pool sequencing. 
UL18 binding peptides for which a protein precursor 
could be identified are derived from intracellular proteins 
(Table 2). The majority of the protein precursors with a 
known function, including glyceraldehyde-3-phosphate de 
hydrogenase, elongation factor 2, actin, ubiquitin carrier 
protein E2, and ribosomal protein L4 are cytoplasmic pro- 
teins (Altschul et al., 1990, and references therein). Other 
protein precursors are also intracellular: j3-galactosidase 
and cathepsin 6 are lysosomal enzymes, and ribophorin 
II is an microsomal integral membrane protein restricted 
to the rough endoplasmic reticulum (Altschul et al., 1990, 
and references therein). This suggests that the HCMV 
class I homolog, like conventional class I molecules, binds 
peptides derived from proteins degraded in the cytoplasm 
(Townsend and Bodmer, 1989). The finding of two pep- 
tides derived from lysosomal proteins was unexpected, 
but could reflect degradation of small amounts of these 
enzymes in the cytoplasm during synthesis. 
Structural Model for the Binding of Peptides 
by the HCMV Class I Homolog 
Structural information about how MHC molecules bind 
peptides, taken together with the sequence alignment of 
UL18 and class I molecules (Beck and Barrell, 1988) sheds 
light upon how UL18 might accommodate peptides within 
an MHC-like groove. Crystallographic studies of class 
I-peptide complexes revealed that the class I MHC prefer- 
immunity 
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Table 2. Peptide Sequences 
Peak Sequence Homologous protein 
1 2 3 4 5 6 7 8 9 1011121314151617181920 
38 LMTTVHAITATQKTV hamster glyceraldehyde-3-phosphate dehydrogenase 
40 ILPDGTXKF rat f3-galactosidase 
46 IMGPNYTPGKKEDLYLKPIQ hamster elongation factor 2 
47 IMEETGKXF human expressed sequence tag clone 
49 LMPNGPMRL human expressed sequence tag clone 
52 VMGGHAIRI rat cathepsin B 
53 ILPEQGLMLT mouse phopholipase APactivating protein 
56 ALPHAILRLD human 8 actin 
56 NLPPHIIRL human ubiquitin carrier protein E2 
62 MMNTDLSRILKSPEIQR rat ribosomal protein L4 
63 ALPHAILRL human 8 chain 
71 TFAPSTI F human ribophorin II 
Bold, full confidence sequence data; not bold, most significant PTH-amino acid, but less than high confidence; X indicates no assignment could 
be made. Each of the peptide sequences was used to search protein and nucleic acid databases (Altschul et al., 1990). Only those sequences 
of peptides for which a protein containing a similar sequence was found in the data base are listed. Sequences derived from the N terminus of 
human f&m (assumed to be a contaminant in the acid eluates) are not included. Some of the same peptides were found in another UL18 acid 
eluate prepared from a different preparation of UL18, including the peptides derived from actin and ribosomal protein L4. 
ence for octamer and nonamer peptide ligands is ex- 
plained by the interaction of the peptide termini with pock- 
ets at each end of the peptide binding site (see Figure 1, 
pockets A and F; reviewed by Stern and Wiley, 1994). 
Most of the residues in these pockets are conserved in 
class I sequences, whereas the intermediate pockets (see 
Figure 1, B-E) contain residues that vary between alleles. 
The side chain at position 2, often an anchor residue, is 
accommodated within pocket 6. Position 2 is clearly an 
anchor residue for the peptides eluted from the HCMV 
homolog, implying that all peptides bind to the viral protein 
with the same respective register; i.e., with their N termini 
fixed. The similarity in characteristics of peptide ligands 
for class I molecules and the HCMV class I homolog is 
consistent with the expectation that the N terminus of a 
UL18 peptide ligand is accomodated in a pocket similar 
to the class I pocket A, and that the side chain of residue 
2 (leucine or methionine) is buried in a hydrophobic pocket 
B. Indeed, these assumptions fit thecharacteristicsof resi- 
h 
0 
30 40 50 60 70 80 90 
Elution time (min) 
Figure 3. Narrowbore Reverse-Phase HPLC Separation of Peptides 
Released from Acid-Dissociated UL18&m Heterodimers 
Upper trace, 210 nm; middle trace, 277 nm; lower trace, 292 nm. 
dues identified by sequence alignment (Beck and Barrell, 
1988) to form pockets A and B of the UL18 protein. The 
critical residues in pocket A of class I molecules are tyro- 
sines 7, 59, 159, and 171, which hydrogen bond directly 
or through a water molecule with main chain atoms of the 
peptide N-terminal residue (Madden et al., 1991; Fremont 
et al., 1992); the corresponding residues of the UL18 pro- 
tein (Beck and Barrell, 1988) are also tyrosines (see Figure 
1). Because of insertions and deletions in the UL18 se- 
quence when compared with class I sequences (Beck and 
Barrell, 1988), it is difficult to assign all of the pocket B 
residues with certainty. However, the UL18 counterpart 
of residue 45 (located at the base of pocket B in class I 
molecules; Saper et al., 1991; Madden et al., 1991; Fre- 
mont et al., 1992) is probably Ala45, a residue that could 
interact favorably with the leucine or methionine side chain 
at position 2 of the peptide ligand. The final residue of class 
I binding peptides is usually hydrophobic (Rammensee 
et al., 1993) and there is a corresponding tendency for 
position 9 of UL18 binding peptides to be hydrophobic 
(Table 2; Figure 4). However, the finding of a number of 
UL18-binding peptides longer than nonamers suggests 
that the pocket F side of the UL18 peptide-binding groove 
differs more from the corresponding portion of class I mole- 
cules than the pocket A side. Indeed, there is a predicted 
insertion of 11 residues at the beginning of the long a helix 
in the a2 domain of the UL18 protein (Beck and Barrell, 
1988) compared with class I molecules, which could mark- 
edly change the properties of the pocket F side of the 
UL18 peptide-binding groove (see Figure 1). Alternatively, 
UL18 could use a similar mechanism as some bona fide 
class I MHC molecules that have been shown to bind pep- 
tides longer than nonamers (Collins et al., 1994; Urban et 
al., 1995). 
Functional Implications for Peptide Binding 
by the HCVM Class I Homolog 
The molecular mechanism of down-regulation of class I 
MHC expression in HCMV-infected cells is unknown, but 
the initial discovery of a viral class I homolog that binds 
Peptide Binding by a Viral Class I MHC Homolog 
507 
Cycle1 Cycle 2 
ij,-. l 1,1... I,1 I .,I _ .I _ 11 I I-- I 
ADEFGHIKLMNPQRSTVWY ADEFGHIKLMNPQRSTVWY 
Cycle 3 Cycle 4 
~~,~m~~ _ ,I ,,I, ! 
ADEFGHIKLMNPQRSTVWY ADEFGHIKLMNPQRSTVWY 
Cycle 5 Cycle 6 
30 30 
m m 
10 10 
0 0 
ADEFGHIKLMNPQRSTVWY 
Cycle 7 Cycle a 
30 30 
20 m 
10 10 
0 0 
ADEFGHIKLMNPQRSTVWY ADEFGHIKLMNPQRSTVWY 
Cycle 9 Cycle 10 
30 
20 
IO  :;. ,p _ .- I 
ADEFGHIKLMNPPRSTVWY ADEFGHIKLMNPQRSTVWY 
Figure 4. Summary of Phenylthiohydantoin Amino Acids Observed from Microsequencing of Reverse-Phase Purified UL19 Binding Peptides 
The X axis corresponds to the number of determinations made for a particular amino acid at the identified cycle; the Y axis shows the single letter 
code for the 19 aa observed. Solid bars, full confidence determinations; cross-hatched bars, most significant amino acid, but less than full confidence. 
Only sequences (n = 30) with six or more cycles of data reported were used in the histograms. 
&rn prompted the suggestion that UL18 sequesters the 
host 8?rn, thereby preventing the maturation of endoge- 
nous class l/f3nm heterodimers (Browne et al., 1990). The 
finding of high levels of free &rn in HCMV-infected cells 
(Beersma et al., 1993) rules out this hypothesis. Further- 
more, UL18 expression cannot be the only mechanism 
of reducing class I expression in host cells, since class I 
expression is reduced in cells infected by a recombinant 
HCMV virus in which the UL18 gene was disrupted 
(Browne et al., 1992). However, expression of the viral 
class I homolog could be part of a multicomponent mecha- 
nism evolved by the virus for reducing the levels of host 
class I molecules. The finding that the HCMV class I homo- 
log binds short peptides derived from cytoplasmic proteins 
is consistent with the hypothesis that UL18, like class I 
molecules, acquires peptides during assembly in the en- 
doplasmic reticulum. Expression of UL18 might therefore 
deplete the supply of peptides available for endogenous 
class I molecules, forcing them to assemble as empty het- 
erodimers, which are significantly less stable than their 
peptide-filled counterparts (Ljunggren et al., 1990; Town- 
send et al., 1990; Fahnestock et al., 1992). The hypothesis 
that UL18 sequesters peptides is consistent with the find- 
ing that HCMV down-regulates class I expression by re- 
ducing the stability of class I heavy chains (Beersma et 
al., 1993), but sequestering peptides is not likely to be a 
mechanism for reducing the stability of all class I alleles 
because only certain kinds of peptides appear able to bind 
to UL18 (Table 2; Figure 4). Another role for peptide bind- 
ing by UL18 could be specifically to bind peptides derived 
from HCMV proteins that might otherwise be presented 
by class I MHC molecules, providing a means for virally 
infected cells to evade the T cell-mediated immune re- 
sponse. However, only a limited subset of viral peptides 
would be able to bind to UL18. 
Although HCMV-infected cells have evolved a mecha- 
immunity 
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nism to elude T cell recognition through down-regulation 
of class I peptides, sequestering antigenic peptides, or 
both, cells that lack class I molecules are normally lysed by 
NK cells (Maudsley and Pound, 1991). Lysis is prevented 
when an inhibitory receptor on the NK cell recognizes a 
class I MHC molecule on the target cell. Recent work has 
shown that NK cell inhibition requires engagement of a 
class I molecule containing peptide (Correa and Raulet, 
1995; Malnati et al., 1995). To evade NK cells, an ideal 
strategy for a virus that down-regulates class I expression 
would be to express a peptide-binding class l-like homo- 
log that is recognized by NK cell inhibitory receptors, but 
not by T cell receptors. The idea that UL18 might engage 
a subset of NK cell inhibitory receptors is supported by 
the observation that NK cells from different strains of mice 
differ in their ability to lyse cells infected with murine CMV 
(MCMV), and the genetic difference maps to the locus 
encoding the inhibitory receptors (Sclazo et al., 1992). 
Taken together with our finding of the peptide binding ca- 
pability of UL18, these observations are consistent with 
the hypothesis that the role of UL18 in a virally infected 
cell is to engage NK cell inhibitory receptors so as to pre- 
vent the lysis that would normally occur because of down- 
regulation of class I MHC molecules. 
Experimental Procedures 
Construction of the ULlg Expression Plasmid 
Molecular cloning manipulations were performed using standard pro- 
tocols (Sambrook et al., 1989). Poiymerase chain reaction (PCR) was 
used to insert a 5’ Xhoi site and a stop codon after the codon corre- 
sponding to amino acid 301 into the UL18 gene (the EcoRl fragment 
G of HCMV, AD169 strain, was provided by Dr. D. Spector, University 
of California, San Diego). (Our numbering scheme starts with the first 
residue of the mature protein assigned as residue 1 and all other 
residues numbered sequentially; see N-terminal sequencing of UL18 
below.) The PCR product was subcloned into Bluescript (Stratagene) 
and the sequence was verified. The modified ULl8 gene was then 
released from Bluescript using Xhol and Notl and subcloned into the 
the unique Xhol and Noti sites of the expression vector PBJB-GS (Gas- 
tine1 et al., 1992). PBJ5-GS carries the glutamine synthetase gene 
as a selectable marker and as a means of gene amplification in the 
presence of the drug methionine sulfoximine, a system developed by 
Celltech (Bebbington and Hentschel, 1987). 
Cell Culture and Transfection 
The UL18 expression plasmid was cotransfected with a previously 
constructed human 6*rn expression vector (Fahnestock et al., 1992, 
1994) into CHO ceils by a lipofectin procedure (GIBCO BRL). Ceils 
resistant to 100 uM methionine suifoximine were selected according 
to the protocol established by Ceiltech, modifications of which have 
been previously described (Gastinel et al., 1992). Transfected CHO 
cells were maintained in glutamine-free aMEM (Irvine Scientific) sup- 
plemented with 10% dialyzed fetal bovine serum (GIBCO BRL), 100 
uM methionine sulfoximine (Sigma), penicillin (100 U/ml), and strepto- 
mycin(100 uglml). Cellssecreting UL181f3zm heterodimerswereidenti- 
fied by immunoprecipitation of supernatants of [?S]methionine meta- 
bolically labeled ceils (see below) using an antibody against human 
6?rn (BBMI; Parham et al., 1963). A radiolabeled polypeptide migrating 
with an apparent molecular mass of 66 kDa was coprecipitated with 
labeled Bzrn from the supernatants of some of the clones, and was 
verified to be the truncated UL16 poiypeptide chain by N-terminal se- 
quencing of the purified protein (see below). 
YG Metabolic Labeling 
ULIB-transfected CHO cells derived from colonies were split into 12- 
well trays, grown to confluence, and incubated in methionine-free me- 
dium plus 1% dialyzed fetal bovine serum for 1 hr. This was followed 
by incubation for 3 hr in 1 .O ml of methionine-free medium plus 1% 
dialyzed fetal bovine serum including 5 uCi of [?S]methionine (Amer- 
sham). Supernatants were clarified by a 5 min spin in a microfuge and 
BBMI monoclonai antibody was added. immunoprecipitations were 
carried out by standard methods (Harlow and Lane, 1988) using protein 
A-bearing Sepharose beads (Pharmacia). Samples were boiled in 
SDS sample buffer and run on 13% polyacryiamide gels, which were 
fixed and prepared for autoradiography using the EN3HANCE (Du- 
Pont) system following the protocol of the manufacturer. 
Protein Purification 
A ULIB-secreting CHO ceil line was grown to confluence in fifty 10 
cm plates. Supernatants were collected every 3 days for 1 month. 
Soluble UL18&m heterodimers were purified from the supernatants 
on a BBMI immunoaffinity column. The affinity column was prepared 
by coupling the BBMI monocional antibody to cyanogen bromide- 
treated Sepharose 48 (Pharmacia) at approximately 10 mg of antibody/ 
ml of resin following the protocol of the manufacturer. Supernatants 
were passed over the affinity column, which was then washed with 
50 column vol of 50 mM Tris (pH 7.4) 0.1% NaN3, 5 mM EDTA. Free 
f&m and UL18&m heterodimers were eluted from the BBMI column 
with 50 mM diethylamine (pH 11.5) into tubes containing 1 .O M Tris 
(pH 7.4). Free f&m was separated from UL18&m heterodimers on a 
Superdex 200 HR IO/30 FPLC gel filtration column. Approximately 
0.25 mg of ULlB&m heterodimers were recovered per liter of 
transfected cell supernatants (as compared with 9-10 mg/liter of 
K”/human 6*rn heterodimers secreted from transfected CHO cells 
grown on IO cm plates; Fahnestock et al., 1994). 
N-Terminal Sequencing of Purified ULl8 
N-terminal sequencing was performed on 4.3 pg of purified soluble 
UL16 in a phosphate buffer dried onto a poiy (vinylidene difluoride) 
membrane and inserted into an Applied Biosystems model 476A se- 
quencer reaction cartridge. Two N-terminal sequences in equimoiar 
amounts were identifed in the UL18 sample (data not shown): the 
sequence IQRTPKIQVYSRHPAENG corresponding to the first 18 resi- 
dues of mature human P2m (Kabat et al., 1991) and the sequence 
HVLRYGYTGIFDDTSHMT corresponding to the first 18 residues of 
the mature UL18 heavy chain (Beck and Barrell, 1988). In our number- 
ing scheme, the histidine at the start of the mature UL18 heavy chain 
is residue 1. in the original publication of the UL18 sequence (Beck 
and Barrell, 1988) it was assumed that two residues preceded this 
histidine, and the rest of their UL18 sequence was numbered with 
reference to class I MHC sequences. Our numbering is sequential 
following the histidine. 
Acid Eiution of Peptides 
Purified secreted UL18 or H-2Kd (a murine class I MHC heavy chain 
complexed with human Plrn; Fahnestock et al., 1992) proteins were 
analyzed for the presence of bound peptides using established meth- 
ods (Van Bieek and Nathenson, 1990; Jardetzky et al., 1991). in brief, 
0.25 mg of protein was concentrated to 100 pi in a centricon 3 (molecu- 
larweight cutoff of 3000)ultrafiitration device(Amicon; Beverly, Massa- 
chusetts). After dilution with 1 .O ml of 50 mM ammonium acetate (pH 
7.5) the proteins were again concentrated to 100 pi, and this procedure 
was repeated. The washed protein was then treated with 1.0 ml of 
12% acetic acid and concentrated again to 100 ul in the ultrafiltration 
unit, and this elution step was repeated. 
Pool Sequencing of Acid Eluates 
The acid eluates were lyophilized and one-sixth of each eluate was 
analyzed by automated Edman degradation using an Applied Biosys- 
terns Model 477A protein sequencer (Table 1). To estimate the percent- 
age of ULI 8 heterodimers occupied with peptide, we made a compari- 
son with the amount of peptides eluted from secreted Kd. Thermal 
stability profiles and analyses of near-ultraviolet CD spectra had pre- 
viously demonstrated that - 70% of Kd/human f&m heterodimers se- 
creted from transfected CHO cells behave as empty molecules (Fahn- 
estock et al., 1992). This estimate is consistent with comparisons of 
the yield from pool sequencing of eluates derived from Kd/murine f&m 
(which appears to be fully occupied) and Kd/human f&m (Fahnestock 
et al., 1994). The maximum number of picomoles of eluted peptides 
Peptide Binding by a Viral Class I MHC Homolog 
589 
expected from the K?human j3*rn acid eluates is therefore only 30% 
of the 895 pmol of input protein (assuming the molecular weight of Kd 
is 80,000 daltons). We recover 175 pmol of amino acids from the Kd 
acid eluates in cycle 1, which corresponds to84% of maximal recovery. 
Applying this factor to account for losses in peptides during elution 
and sequencing, the 378 pmol of amino acids in cycle 1 of the UL18 
acid eluate implies that the UL18 acid eluate originally contained 447 
pmol of peptides. This amount was eluted from 482 pmol of UL18 
protein (assuming a molecular weight of 90,000 daltons). Since quanti- 
tation of a single amino acid should be more accurate than quantita- 
tions based upon sums of many different amino acids, the calculation 
was repeated using the amount of the tyrosine anchor residue recov- 
ered in cycle 2 of the Kd eluate sequence for yield estimates rather 
than the total number of picomoles recovered in cycle 1. The 77 pmol 
of tyrosine in position 2 implies a 37% recovery of available peptides 
by the second sequencing cycle, a percent recovery that has been 
typical for our work with Kd acid eluates (Raghavan et al., 1993; Fahne- 
stock et al., 1994). The recovery of 175 pmol of anchor residues in 
cycle 2 of the pool sequence of peptides eluted from UL18 suggests 
that the UL18 acid eluate originally contained 472 pmol of peptides. 
These calculations suggest that essentially all (970/o-100%) of the 
secreted UL18 heterodimers contain bound peptide. 
Isolation and Sequencing of Peptides 
Peptides released from UL18&m heterodimers were separated by 
narrowbore reverse-phase HPLC as previously described (Jardetzky 
et al., 1991; Lane et al., 1991). Fractions were collected by peak while 
detecting UV absorbance at 210 nm. To optimize peak selection for 
sequencing, fractions were simultaneously monitored at 277 nm and 
292 nm. Ratios between these wavelengths provides differentiation 
of tryptophan: from tyrosine-containing peptides, and the exclusion of 
nonpeptide artifact peaks (Lane et al., 1991). Isolated peptides were 
purified and microsequenced using an ABI 477A protein sequencer 
with a 120A PTH-AA analyzer as described (Lane et al., 1991). 
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